October 2024
September 2024
April 2024
Aspa Therapeutics ‘BBP-812 Gene Therapy Program for Canavan Disease: Updates
October 2023
May 2023
New findings from the CANaspire Trial shared during a platform presentation at the 26th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
October 2022
Encouraging data from the CANaspire gene therapy trial shared during a poster presentation at the 51st Annual Meeting of the Child Neurology Society
June 2022
New data from the CANaspire gene therapy clinical trial shared in recent press release
April 2022
Preliminary observations from CANaspire, Aspa’s clinical trial of intravenous (IV) AAV9 gene therapy for Canavan disease
October 2021
First participant in the CANaspire clinical trial has been dosed with Aspa’s investigational gene therapy for Canavan disease
August 2021
Participant screening begins at first clinical trial site in the United States
You are leaving our website and we cannot be held responsible for the content of external websites.
